Also known as Egrifta
GHRH analog FDA-approved for HIV-associated lipodystrophy.
Tesamorelin is a stabilized 44-amino-acid GHRH analog approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Tesamorelin is a stabilized 44-amino-acid analog of growth-hormone-releasing hormone (GHRH). By stimulating the pituitary to release endogenous GH, it preserves more of the body’s natural feedback than exogenous GH would.
It is FDA-approved (Egrifta, 2010) specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Beyond that indication it has been studied for visceral adiposity more broadly and, in research settings, for effects on cognition.
GHRH receptor agonism → endogenous GH release.
Behind every vial of Tesamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Tesamorelin, specifically, is brought into being.
On paper, Tesamorelin is C221H366N72O67S — about 5,135.9 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Tesamorelin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Tesamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Tesamorelin proves itself: identity confirmed by mass spectrometry against its ~5,135.9 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Tesamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Tesamorelin to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Tesamorelin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Tesamorelin is a GHRH analog FDA-approved (Egrifta) to reduce excess abdominal fat in people with HIV-associated lipodystrophy.
It stimulates the pituitary to release the body’s own growth hormone, rather than supplying GH directly.
Reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Other uses described here are research contexts, not approved indications.
No — this page is a research and educational reference, not medical advice or a dosing protocol.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.